Trade Aquestive Therapeutics, Inc. - AQST CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0330 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.0485 |
| Open | 3.0485 |
| 1-Year Change | 15.68% |
| Day's Range | 2.9985 - 3.1185 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 2.9985 | -0.0300 | -0.99% | 3.0285 | 3.1285 | 2.9985 |
| Feb 20, 2025 | 3.0485 | 0.0600 | 2.01% | 2.9885 | 3.1885 | 2.9285 |
| Feb 19, 2025 | 3.0085 | -0.0600 | -1.96% | 3.0685 | 3.1285 | 2.9885 |
| Feb 18, 2025 | 3.1285 | -0.1400 | -4.28% | 3.2685 | 3.3485 | 3.0385 |
| Feb 14, 2025 | 3.3085 | -0.0900 | -2.65% | 3.3985 | 3.5185 | 3.3085 |
| Feb 13, 2025 | 3.4585 | 0.1100 | 3.29% | 3.3485 | 3.5985 | 3.2185 |
| Feb 12, 2025 | 3.3785 | 0.5000 | 17.37% | 2.8785 | 3.3985 | 2.8785 |
| Feb 11, 2025 | 2.9585 | 0.0300 | 1.02% | 2.9285 | 2.9785 | 2.8885 |
| Feb 10, 2025 | 2.9785 | 0.0500 | 1.71% | 2.9285 | 2.9985 | 2.9285 |
| Feb 7, 2025 | 2.9185 | -0.0400 | -1.35% | 2.9585 | 3.0285 | 2.8885 |
| Feb 6, 2025 | 2.9985 | -0.0600 | -1.96% | 3.0585 | 3.1085 | 2.9985 |
| Feb 5, 2025 | 3.0785 | 0.1000 | 3.36% | 2.9785 | 3.1085 | 2.9785 |
| Feb 4, 2025 | 3.0485 | 0.1700 | 5.91% | 2.8785 | 3.0585 | 2.8785 |
| Feb 3, 2025 | 2.8685 | -0.0500 | -1.71% | 2.9185 | 2.9785 | 2.8585 |
| Jan 31, 2025 | 2.9985 | -0.0500 | -1.64% | 3.0485 | 3.0885 | 2.9785 |
| Jan 30, 2025 | 3.0585 | 0.0000 | 0.00% | 3.0585 | 3.1485 | 3.0085 |
| Jan 29, 2025 | 3.0785 | -0.0500 | -1.60% | 3.1285 | 3.1385 | 3.0685 |
| Jan 28, 2025 | 3.1285 | 0.1800 | 6.10% | 2.9485 | 3.1385 | 2.9385 |
| Jan 27, 2025 | 2.9685 | -0.0700 | -2.30% | 3.0385 | 3.1385 | 2.9585 |
| Jan 24, 2025 | 3.0685 | 0.0200 | 0.66% | 3.0485 | 3.1485 | 3.0285 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aquestive Therapeutics, Inc. Company profile
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing differentiated products which leverage PharmFilm. Its late-stage product pipeline focused on the treatment of central nervous system (CNS), diseases and an earlier stage pipeline including treatment of anaphylaxis. Its commercialized licensed product is Suboxone, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Its CNS portfolio focused on epilepsy includes, Sympazan an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome (LGS). Its portfolio also includes Suboxone a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist for the treatment of opioid dependence.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aquestive Therapeutics Inc revenues increased 11% to $50.8M. Net loss increased 26% to $70.5M. Revenues reflect Ex-United States segment increase of 63% to $8M, United States segment increase of 5% to $42.9M. Higher net loss reflects Interest expense related to the sale increase from $2M to $12.4M (expense), Stock-based Compensation in R&D increase of 21% to $881K (expense).
Equity composition
Common Stock $.01 Par, Shares auth. and o/s after the offering: 100M auth., 15,029,412 issd. Insiders own approx. 1% (after the IPO). IPO: TBA. 4M shares Offered. 03/08, IPO withdrawn.
| Industry: | Pharmaceuticals (NEC) |
30 Technology Dr
WARREN
NEW JERSEY 07059-5166
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com